Literature DB >> 18508931

Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies.

Veenu Minhas1, Lynsey N Crosby, Kay L Crabtree, Saul Phiri, Tendai J M'soka, Chipepo Kankasa, William J Harrington, Charles D Mitchell, Charles Wood.   

Abstract

Human herpesvirus 8 (HHV-8), or Kaposi's sarcoma (KS)-associated herpesvirus, has been linked to all forms of KS. The results of most current serological assays for the detection of HHV-8-specific antibodies have low levels of concordance among themselves. To establish a sensitive and specific testing strategy that can be used to screen for HHV-8-specific antibodies, three HHV-8 proteins, ORF65, ORF73, and K8.1A, were expressed by using baculoviral vectors in insect cells and incorporated into a monoclonal antibody-enhanced immunofluorescence assay (mIFA) termed the Sf9 three-antigen mIFA. The results obtained by this mIFA were compared to those obtained by a standard mIFA with an HHV-8-infected B-cell line (BC3 mIFA). Test sera were obtained from patients diagnosed with KS, human immunodeficiency virus type 1-infected patients at high risk for HHV-8 infection, and healthy controls from a local blood bank. The combined use of both assays had a sensitivity of 94% and a specificity of 96%. The performance of these two assays when they were used together indicates that they may be useful for the reliable detection of HHV-8-specific immunoglobulin G antibodies in a population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508931      PMCID: PMC2519300          DOI: 10.1128/CVI.00487-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta.

Authors:  E A Engels; M D Sinclair; R J Biggar; D Whitby; P Ebbesen; J J Goedert; J L Gastwirth
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

2.  Vertical transmission of Kaposi's sarcoma-associated herpesvirus.

Authors:  H Mantina; C Kankasa; W Klaskala; B Brayfield; J Campbell; Q Du; G Bhat; F Kasolo; C Mitchell; C Wood
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

3.  Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS.

Authors:  E B Quinlivan; R X Wang; P W Stewart; C Kolmoltri; N Regamey; P Erb; P L Vernazza
Journal:  J Med Virol       Date:  2001-06       Impact factor: 2.327

4.  Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays.

Authors:  O Schatz; P Monini; R Bugarini; F Neipel; T F Schulz; M Andreoni; P Erb; M Eggers; J Haas; S Buttò; M Lukwiya; J R Bogner; S Yaguboglu; J Sheldon; L Sarmati; F D Goebel; R Hintermaier; G Enders; N Regamey; M Wernli; M Stürzl; G Rezza; B Ensoli
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

5.  Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma.

Authors:  H Katano; T Iwasaki; N Baba; M Terai; S Mori; A Iwamoto; T Kurata; T Sata
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Mucosal shedding of human herpesvirus 8 in men.

Authors:  J Pauk; M L Huang; S J Brodie; A Wald; D M Koelle; T Schacker; C Celum; S Selke; L Corey
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

7.  Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors.

Authors:  P E Pellett; D J Wright; E A Engels; D V Ablashi; S C Dollard; B Forghani; S A Glynn; J J Goedert; F J Jenkins; T-H Lee; F Neipel; D S Todd; D Whitby; G J Nemo; M P Busch
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

8.  Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission.

Authors:  Brad P Brayfield; Chipepo Kankasa; John T West; Jubra Muyanga; Ganapati Bhat; Winslow Klaskala; Charles D Mitchell; Charles Wood
Journal:  J Infect Dis       Date:  2004-05-25       Impact factor: 5.226

9.  Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area.

Authors:  Veenu Minhas; Kay L Crabtree; Ann Chao; Tendai J M'soka; Chipepo Kankasa; Marc Bulterys; Charles D Mitchell; Charles Wood
Journal:  Am J Epidemiol       Date:  2008-05-30       Impact factor: 4.897

Review 10.  Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma.

Authors:  M Dedicoat; R Newton
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  17 in total

1.  High prevalence of early childhood infection by Kaposi's sarcoma-associated herpesvirus in a minority population in China.

Authors:  Y Cao; V Minhas; X Tan; J Huang; B Wang; M Zhu; Y Gao; T Zhao; L Yang; C Wood
Journal:  Clin Microbiol Infect       Date:  2013-08-28       Impact factor: 8.067

2.  Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis.

Authors:  Landon N Olp; Danielle M Shea; Maxine K White; Clement Gondwe; Chipepo Kankasa; Charles Wood
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

3.  The Zambia Children's KS-HHV8 Study: rationale, study design, and study methods.

Authors:  Veenu Minhas; Kay L Crabtree; Ann Chao; Janet M Wojcicki; Adrian M Sifuniso; Catherine Nkonde; Chipepo Kankasa; Charles D Mitchell; Charles Wood
Journal:  Am J Epidemiol       Date:  2011-03-28       Impact factor: 4.897

4.  Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.

Authors:  Georgina L Mbisa; Wendell Miley; Christine J Gamache; William K Gillette; Dominic Esposito; Ralph Hopkins; Michael P Busch; George B Schreiber; Richard F Little; Robert Yarchoan; Betty A Ortiz-Conde; Nazzarena Labò; Denise Whitby
Journal:  J Immunol Methods       Date:  2010-03-04       Impact factor: 2.303

5.  Seroprevalence of human herpesvirus 8 and its impact on the hemoglobin level in patients of end stage of renal diseases.

Authors:  Qiwen Fang; Xiaoyi Wang; Zhenqiu Liu; Ming Zhu; Min Ding; Veenu Minhas; Charles Wood; Tiejun Zhang
Journal:  J Med Virol       Date:  2017-09-22       Impact factor: 2.327

6.  Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.

Authors:  T Zhang; N He; Y Ding; K Crabtree; V Minhas; C Wood
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

7.  Antibody responses to lytic and latent human herpesvirus 8 antigens among HIV-infected patients in central China.

Authors:  T J Zhang; N He; Y Y Ding; Q W Jiang; C Wood
Journal:  Biosci Trends       Date:  2012-06       Impact factor: 2.400

8.  Kaposi's Sarcoma-Associated Herpesvirus Infection of Neurons in HIV-Positive Patients.

Authors:  For Yue Tso; Ashley Sawyer; Eun Hee Kwon; Victor Mudenda; Dianne Langford; You Zhou; John West; Charles Wood
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

9.  Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.

Authors:  Salum J Lidenge; For Yue Tso; Owen Ngalamika; John R Ngowi; Yasaman Mortazavi; Eun Hee Kwon; Danielle M Shea; Veenu Minhas; Julius Mwaiselage; Charles Wood; John T West
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

10.  Primary gamma-herpesviral infection in Zambian children.

Authors:  Veenu Minhas; Brad P Brayfield; Kay L Crabtree; Chipepo Kankasa; Charles D Mitchell; Charles Wood
Journal:  BMC Infect Dis       Date:  2010-05-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.